



Exelixis Announces August 12 Webcast of Presentation at the Canaccord Genuity 30th Annual Growth Conference

August 6, 2010

SOUTH SAN FRANCISCO, Calif., Aug 06, 2010 (BUSINESS WIRE) --

Exelixis, Inc. (NASDAQ:EXEL) announced today that Charles Butler, the company's vice president of investor relations and corporate communications, will present at the Canaccord Genuity 30th Annual Growth Conference at 10:30 a.m. EDT / 7:30 a.m. PDT on Thursday, August 12, 2010 in Boston. Mr. Butler will discuss the company's corporate strategy, development pipeline and financial outlook, and provide a general business update.

The event will be webcast and may be accessed in the Event Calendar page under Investors and Media at <http://www.exelixis.com>.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its biological expertise and integrated research and development capabilities to generate a pipeline of development compounds with significant therapeutic and commercial potential for the treatment of cancer and potentially other serious diseases. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 3, phase 2, and phase 1 clinical development. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including Bristol-Myers Squibb Company, sanofi-aventis, GlaxoSmithKline, Genentech (a wholly owned member of the Roche Group), Boehringer Ingelheim, and Daiichi-Sankyo. For more information, please visit the company's web site at <http://www.exelixis.com>.

Exelixis and the Exelixis logo are registered U.S. trademarks.



SOURCE: Exelixis, Inc.

Exelixis, Inc.

Investor Contacts:

Charles Butler, 650-837-7277

Vice President,

Investor Relations

and Corporate Communications

cbutler@exelixis.com

DeDe Sheel, 650-837-8231

Associate Director,

Investor Relations

dsheel@exelixis.com